Innovative new E. Coli solution for nursery pigs now available

Developed for animal use only, Surmax® 200 is a first-in-class antibiotic

Surmax® 200, a new swine product from Elanco Animal Health, represents a first-in-class, animal-use only antibiotic for reduction in the incidence and severity of diarrhea in the presence of pathogenic Escherichia coli in groups of weaned pigs. Surmax® 200 is an orthosomycin antibiotic, a new class of antibiotics now on the market for animal use only. Administered solely under the direction of a veterinary feed prescription, Surmax® 200 is a solution for pigs up to 14 weeks of age. Fed continuously for 21 days based on clinical assessment, Surmax® 200 is administered in feed to pigs at risk of developing, but not yet showing clinical signs of, diarrhea. Surmax® 200 features a zero-day withdrawal period.

A 2011 efficacy trial compared diarrhea incidence rates* among newly weaned pigs who received Surmax® 200 (80 g/tonne) and a non-medicated control group. The trial found a 31.2% reduction1 (p<0.01)in diarrhea incidence rate in pigs that received Surmax® 200 compared to the non-medicated control group1.

As one of the most important causes of post-weaning diarrhea in pigs2, E. coli can significantly impact herd health and performance. “Elanco Animal Health Canada is excited to be incorporating Surmax 200 into our strong portfolio of products to manage post weaning diarrhea due to E. Coli” said Trenna Derdall, Monogastric Director Elanco. “With the increasing complexity of E. Coli in Canada and the challenges this creates for veterinarians and producers, we are pleased to offer a comprehensive range of solutions.”


Surmax® 200 Important Safety Information


  • As Surmax® 200 Premix is only indicated for use in weaned pigs, responsible antimicrobial use limits its use to pigs less than 14 weeks of age.

  • The effectiveness of Surmax® 200 Premix has only been demonstrated when avilamycin-medicated feed was offered before the onset of diarrhea. Use of Surmax® 200 Premix for the treatment of established cases of clinical diarrhea in weanling pigs has not been demonstrated.  

  • Elanco provides comprehensive products and knowledge services to improve animal health and food-animal production in more than 70 countries around the world. We value innovation, both in scientific research and daily operations, and strive to cultivate a collaborative work environment for more than 6,500 employees worldwide. Together with our customers, we are committed to raising awareness about global food security, and celebrating and supporting the human-animal bond. Founded in 1954, Elanco is a division of Eli Lilly and Company. Our worldwide headquarters and research facilities are located in Greenfield, Indiana. Visit us at and


    *Diarrhea incidence rate = (sum of diarrhea scores) / (total head days) x 100

    1Elanco Animal Health. Clinical Study (GCP):Efficacy of Avilamycin Administered in Feed for Reduction of Incidence and Severity of Nursery Pig Colibacillosis Study Numbers T4EUS100011, T4EUS100012, T4EUS110002, and T4EUS110003. 2011;n/a:1-188.

    2Fairbrother JM, Nadeau E, Gyles CL. 2005. Escherichia coli in postweaning diarrhea in pigs: an update on bacterial types, pathogenesis, and prevention strategies. Animal Health Research Reviews, 6(1):17-39.


Elanco®, Surmax®, and the diagonal bar are trademarks owned by or licensed to Eli Lilly and Company, its affiliates or subsidiaries.

© 2016 Eli Lily and Company, or its affiliates.CASWISUR00023